Safety Summary of Pediatric Inflammatory Bowel Disease Therapies

Abstract

Therapeutic options for the treatment of pediatric inflammatory bowel disease include aminosalicylates, enteral nutrition , corticosteroids, immunomodulators , biologics, and emerging small molecule agents. Infectious risk due to systemic immunosuppression should be mitigated by appropriate screening before therapy initiation. Rare but serious malignancies have been associated with thiopurine use alone and in combination with anti-tumor necrosis factor agents, often in the setting of a primary Epstein–Barr virus infection. Potential agent-specific adverse events such as cytopenias , hepatotoxicity , and nephrotoxicity warrant regular clinical and laboratory monitoring.